Ultragenyx Pharmaceutical (RARE) Gross Profit Growth (3y) (2021 - 2026)
Ultragenyx Pharmaceutical (RARE) Gross Profit Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 54.36% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.16% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.86% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 79.18% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.71 Bn | 2.30 Bn | 106.00 Mn | 6.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.30% |
| Dec 31, 2025 | 21.98% |
| Sep 30, 2025 | 17.15% |
| Jun 30, 2025 | 20.96% |
| Mar 31, 2025 | 14.21% |
| Dec 31, 2024 | 22.68% |
| Sep 30, 2024 | 15.21% |
| Jun 30, 2024 | 14.47% |
| Mar 31, 2024 | -1.04% |
| Dec 31, 2023 | 10.24% |
| Sep 30, 2023 | 3.24% |
| Jun 30, 2023 | 17.99% |
| Mar 31, 2023 | 39.07% |
| Dec 31, 2022 | 47.60% |
| Sep 30, 2022 | 52.55% |
| Jun 30, 2022 | 51.35% |
| Mar 31, 2022 | 60.92% |
| Dec 31, 2021 | 71.80% |
| Sep 30, 2021 | 88.92% |
| Jun 30, 2021 | 87.82% |